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Crystal structure of cathepsin X: a flip–flop of the ring of His23
allows carboxy-monopeptidase and carboxy-dipeptidase activity
of the protease
Gregor Guncar1, Ivica Klemencic1, Boris Turk1, Vito Turk1,
Adriana Karaoglanovic-Carmona2, Luiz Juliano2 and Dušan Turk1*
Background: Cathepsin X is a widespread, abundantly expressed papain-like
mammalian lysosomal cysteine protease. It exhibits carboxy-monopeptidase as
well as carboxy-dipeptidase activity and shares a similar activity profile with
cathepsin B. The latter has been implicated in normal physiological events as
well as in various pathological states such as rheumatoid arthritis, Alzheimer’s
disease and cancer progression. Thus the question is raised as to which of the
two enzyme activities has actually been monitored.
Results: The crystal structure of human cathepsin X has been determined at
2.67 Å resolution. The structure shares the common features of a papain-like
enzyme fold, but with a unique active site. The most pronounced feature of the
cathepsin X structure is the mini-loop that includes a short three-residue
insertion protruding into the active site of the protease. The residue Tyr27 on
one side of the loop forms the surface of the S1 substrate-binding site, and
His23 on the other side modulates both carboxy-monopeptidase as well as
carboxy-dipeptidase activity of the enzyme by binding the C-terminal carboxyl
group of a substrate in two different sidechain conformations.
Conclusions: The structure of cathepsin X exhibits a binding surface that will
assist in the design of specific inhibitors of cathepsin X as well as of cathepsin
B and thereby help to clarify the physiological roles of both proteases.
Introduction
Cathepsin X belongs to the group of lysosomal cysteine
proteases, which constitute a numerous and important part
of the family of papain-like enzymes (clan CA; reviewed
in [1]). The research interest in this field is increasing
rapidly, together with the number of identified enzymes,
as it becomes evident that lysosomal cysteine proteases
are, besides being involved in intracellular protein catabo-
lism, also involved in a number of important cellular
processes [2,3]. Currently 11 human cathepsins are known
at the sequence level (B, C, F, H, K, L, O, S, V, W and X).
Some of them are expressed in a wide variety of cells (B,
C, F, H, L, O and X), whereas others (S, K, V and W) are
tissue-specific and have been shown to be or proposed to
be involved in more specialized processes (reviewed in
[3]). They are involved in invariant chain processing and
antigen presentation [4–7], in bone remodeling [8–10] and
in proteolytic processing of various proteins [11], among
these the most important being thyroglobulin [12–14] and
granzyme B [15]. Whereas the former is an important
source of thyroglobulin hormones the latter is involved in
the activation of the cell death proteases, the caspases
(reviewed in [3]). Besides their normal physiological roles,
lysosomal cysteine proteases are involved in a number of
pathological processes such as tumor malignancy and pro-
gression (reviewed in [16–18]), muscular dystrophy [19],
rheumatoid arthritis [20], osteoporosis and other bone dis-
orders [2,10,21] and Alzheimer’s disease [22].
Cathepsin X was discovered only recently [23–25] and its
biochemical characterization is just emerging [25–27]. It is
the only known lysosomal cysteine protease exhibiting
carboxy-monopeptidase activity. Besides carboxy-
monopeptidase activity cathepsin X also exhibits carboxy-
dipeptidase activity and is readily inhibited by CA074,
previously known as the specific inhibitor of cathepsin B,
which is the only known carboxy-dipeptidase among lyso-
somal cysteine proteases (I.K. et al., unpublished observa-
tions). The inhibitor has been used as a standard tool to
assess functions of cathepsin B in numerous in vivo and in
vitro studies, for example in relation with exocytosis [28]
and cancer (reviewed in [16,18,29]). Similarly, the implica-
tion of cathepsin X in the development of Alzheimer’s
disease is based on the use of inhibitors [27] and therefore
requires confirmation.
A structural investigation of the active site of cathepsin X is,
therefore, a mandatory step for understanding the specific
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features of cathepsin X in order to establish the structural
basis of the specificity of similar cathepsins, in particular
cathepsin B. This will enable us to design substrates and
inhibitors that will address specifically only the desired
enzyme. It has already been suggested, from sequence data
and a substrate study [26], that a short insertion of residues
24–26, which constitutes the tip of the mini-loop placed in
the immediate vicinity of the reactive site, must be
involved in interaction with substrate. It was also suggested
[26] that the mini-loop residue His23 is involved in recogni-
tion and binding of the C-terminal carboxylic group of a
bound substrate. The crystal structure of cathepsin X pre-
sented here has enabled us to elucidate the structural basis
of the mechanism by which cathepsin X exhibits both
carboxy-monopeptidase and carboxy-dipeptidase activity.
Results
Overall structure
The structure of human cathepsin X comprises the
sequence of the whole mature single-chain protein of 242
amino acid residues, which are numbered consecutively
from Leu1 to Val242. The asymmetric unit of orthorhom-
bic crystals contains two molecules. The three-dimen-
sional structures of the two molecules are almost identical.
The complete chains of both molecules, with the excep-
tion of a few sidechain residues, are well resolved in the
electron-density maps. The superimposed structures show
a root mean square deviation (rmsd) of 0.55 Å for all Cα
atoms; when only residues included into noncrystallo-
graphic symmetry (NCS) constraints are used for Cα atom
superposition (235 residues), the resulting rms fitting pro-
cedure yields a considerably lower value (0.26 Å).
The structure possesses the typical fold of a papain-like
cysteine protease, a two domain structure [30,31]. The
predominant secondary structural features of the N-termi-
nal domain on the left, or L domain, are α helices, whereas
the C-terminal domain, or R domain, has a β-barrel fold
(Figure 1). The two domains interact along an extended
interface, reminiscent of a book with the spine in front. At
the top the two domains separate and form a ‘V-shaped’
active-site cleft with the reactive site residues, Cys31 and
His180, each coming from a different domain.
The structure of cathepsin X, as judged from a number of
superimposed pairs, is rather similar to the structures of
human cathepsin K, rat cathepsin B, zymogen of cathepsin
L and papain (yielding respectively 145, 148, 146 and 141
equipositioned Cα pairs at a threshold distance of 1.5 Å).
It is less similar to cathepsin L, actinidin, glycyl-endopep-
tidase I and cruzipain (yielding 122, 116, 128 and 130
pairs) and least similar to human cathepsin B and porcine
cathepsin H (with 89 and 73 pairs; Figure 2). Although by
numerical criteria the structure of cathepsin X does not
superimpose on the structure of cathepsin B as well as on
those of other related enzymes, a visual inspection reveals
that the structures of cathepsin B, and to a smaller extent
cathepsin H, are the most similar in the position and archi-
tecture of the surface loops to the structure of cathepsin X.
Some outstanding loops of the cathepsin X structure
(110–123 and 189–193) appear at similar positions to some
cathepsin B loops (132–139 and 208–212). Particularly
striking is the exposed position of the ring of Phe115,
placed at the tip of the 110–123 loop. The short three-
residue insertion (Ile24, Pro25 and Gln26) appears to be of
particular importance for the specificity of cathepsin X. It
is located within the mini-loop (Figure 3), an otherwise
conserved loop between Gln19 and Cys25 (using papain
numbering), forming the wall of the S2′ substrate-binding
site [32]. An exception is the loop of glycyl-endopepti-
dase, in which a tyrosine residue replaces the conserved
Ser21 (papain numbering).
The mature form of human cathepsin X contains 11 cys-
teine residues. Ten of them are involved in disulfide bonds
(28–71, 65–103, 93–109, 112–118 and 153–235). The only
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Figure 1
Structure of cathepsin X. (a) Ribbon diagram of cathepsin X (blue
ribbons) in the standard view with the mini-loop shown in green. The
His23, Tyr27 mini-loop sidechains are shown in green and the
Cys31 catalytic residue sidechain in yellow. Disulfide bridges are
shown as orange sticks. The figure was prepared using the program
RIBBONS [52]. (b) A stereo plot of the Cα trace of cathepsin X. The
dotted lines represent disulphide bridges.
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sulfhydryl group of the enzyme that is accessible to solvent
is the active site Cys31, which appears to be blocked by a
small unidentified group as revealed by the final difference
electron-density maps (2Fo–Fc; Figure 3). The disulfides
65–103 and 28–71 are well conserved among the papain-
like enzyme structures. Like cathepsin B, cathepsin X
does not have the disulfide 153–200 (using papain number-
ing) to fix the upper loops defining the S2 and S1′ sub-
strate binding sites. Instead there is a disulfide 153–235
much lower in the core of the β barrel domain, which is
absent in the related structures. The disulfide 93–109 has
an equivalent only in the cathepsin B structure (100–132),
whereas the cathepsin X disulfide 112–118 appears to be
unique within the family of papain-like enzymes.
Two cis prolines, Pro25 and Pro53, have been resolved in
the structure. The Pro25 is positioned on the tip of the
mini-loop.
Active-site cleft
The active-site cleft of cathepsin X is reminiscent of
related endopeptidases. It is a V-shaped canyon with no
features similar to the occluding loop of carboxy-dipepti-
dase cathepsin B [33] or the mini-chain of amino-pepti-
dase cathepsin H [34], which block access to a substrate. A
closer inspection, taking into account the sidechains,
shows that the positions of the otherwise conserved
residues (Gly20 and Ser21 using papain numbering) are
occupied by His23 and Tyr27. The Gly20 and Ser21 in all
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Figure 2
Structural based alignment of the sequences
of cathepsin X (catx) with cathepsin B (1huc
[33]), cathepsin H (8pch [34]), cathepsin L
(1icf [53]) and papain (9pap [54]). Identical
residues are shaded in black and similar
residues are in gray. 
Figure 3
A stereoview of the final 2Fo–Fc electron-
density map of the cathepsin X active site
contoured at 1.3 σ (blue) superimposed on a
stick model of cathepsin X. The cathepsin X
molecule is shown in orange and the mini-loop
is in green. The oxygen, nitrogen and sulfur
atoms are represented as small spheres in red,
blue and yellow, respectively. Water molecules
are drawn as pink spheres. The figure was
prepared with the program MAIN [49].
st8308.qxd  03/22/2000  11:36  Page 307
other known structures of the papain-like enzymes form a
short loop with the serine sidechain pointing away from
the active-site cleft, whereas the three residue insertion
(Ile24, Pro25 and Gln26) forces the His23 and Tyr27 into
an extended conformation with their sidechains intruding
into the active site cleft of the enzyme. The imidazole
ring of His23 attaches to the surface of the mini-loop
(Gln22–Cys31; Gln19–Cys25, using papain numbering)
and actually occupies the place, which in equivalent struc-
tures is the S2′ substrate-binding site. The arrangement is
similar to that in cathepsin H, in which Thr83P fills the S2
substrate-binding site. The difference is that in cathepsin
H the C-terminal carboxylic group binds the N terminus
of a bound substrate, whereas in cathepsin X the car-
boxylic group of a bound substrate is attracted by the posi-
tively charged sidechain of His23.
The active-site cleft in cathepsin X thus comprises sub-
strate-binding sites S2, S1 and S1′ [31,32]. The conserved
catalytic residues, Cys31 and His180, and the functional
groups of residues involved in interaction with a substrate
mainchain are observed at the expected positions. The
amide proton on Nε1 of Trp202 is in a position to bind the
carbonyl of the P1′ residue. The oxyanion hole between the
Gln22 sidechain and the amide of Cys31 positioned at the
N terminus of the central α helix from the L domain can
bind the carbonyl of the P1 residue. Gly74 (Gly66 in
papain) provides its amide proton as well as carbonyl oxygen
to form a short antiparallel β-leader hydrogen bonded
arrangement with the mainchain carbonyl and amide group
of a bound P2 residue. The interaction between the car-
bonyl and the electrostatic positive potential at the edge of
the highly conserved Trp32 is evident [32].
With the extended mainchain of Ala157 and Thr158
forming a substantial part of the surface of the S1′ site,
cathepsin X joins the group of cathepsins B and H, in con-
trast to other related enzymes (cathepsins K, L and S,
papain, actinidin and others), in which an additional
residue twists the chain-trace into a short curve. In cathep-
sin B the S1′ binding site is enclosed from the top by the
unique trace of the loop between Phe174 and His199,
whereas cathepsin H has a valine residue at the position of
Ala157. The S1′ binding site of cathepsin X is thus the
largest among the related cathepsins of which the struc-
tures are known.
In the related papain-like proteases the sidechain of a
bound substrate P1 residue is in contact with the shallow
groove of the S1 binding site formed between Ser21,
Cys22 and Gly23 (papain numbering) and Cys65, Asn64,
Gly66 on the other side bridged by the disulfide
Cys22–Cys65 (papain numbering). (An exception is
glycyl-endopeptidase, in which the Glu23 of the enzyme
fills the space that is normally occupied by the moiety of
the sidechain.) In the cathepsin X structure, however, the
groove is much deeper because of the Tyr27 benzoyl ring,
which points downwards towards the catalytic cysteine
residue, demarcating the region between the S1 and S2′
binding site. The Glu72 sidechain, which points upwards
on the other side of the S1 pocket, provides a negative
charge, which is not unique for a papain-like enzyme. A
similar negative charge is provided by Asp72 in actinidin,
whereas the occluding loop residue Glu122 in cathepsin B
enters the S1 binding site from the opposite side (the side
of Tyr27 in cathepsin X). The interactions between the
P1 residue and the S1 binding site of cathepsin X thus
appear to be tighter and also more selective than in the
other related proteases.
The place where the P2 residue sidechain binds to the
cathepsin X is, as in other related proteases, the only sub-
strate site that can be called a pocket [32]. In most papain-
like cysteine proteases this site is hydrophobic. The
surface of the pocket in cathepsin X also has predomi-
nantly hydrophobic character with Val181 at the bottom
and Gly154 and Ile178 on the right. Ser205 (papain num-
bering) is in general quite conserved, exceptions being
cathepsin B and cruzipain with a glutamic acid. Out of
those related enzymes for which structures are known,
cathepsin X is the only one with a histidine residue
(His234) at this position. In addition, the specific character
of the S2 pocket is modulated in cathepsin X by Asp76,
which is a hydrophobic residue in other related structures,
usually methionine or proline. The Asp76–His234 arrange-
ment presumably enables cathepsin X to process substrates
with long sidechains with a hydrophilic tail at position P2.
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Figure 4
Chemical structures of CA074 and CA030 inhibitors.
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Discussion
Carboxy-monopeptidase and carboxy-dipeptidase activities
of cathepsin X
A kinetic study has shown that cathepsin X can act not only
as a carboxy-monopeptidase as shown by Nägler et al. [26]
but also as carboxy-dipeptidase (I.K. et al., unpublished
observations) Of the substrates DnpGFFFW-OH,
DnpGRFFW-OH, DnpGFRFW-OH and DnpGFFRW-
OH (sequences in single-letter amino acid code), it has
been found that cathepsin X cleaves the last two C-terminal
residues from DnpGFRFW-OH. In addition, cathepsin X
can be readily inhibited by CA074 (I.K. et al., unpublished
observations), which was previously believed to be specific
for cathepsin B. CA074 is an epoxysuccinyl-based inhibitor
(Figure 4) with its isoleucine–proline dipeptide mimicking
substrate binding in the S1′ and S2′ binding sites [35–37].
We therefore used the crystal structure of CA030 in
complex with cathepsin B and the proposed substrate
model [37] as a template for the modeling of the geometry
of substrates bound into the active cleft of cathepsin X
(Figure 5). Models of AFFW and AFRFW peptide
sequences were used to investigate the mechanisms of
carboxy-peptidase and carboxy-dipeptidase activities. The
results of the modeling study suggest that the proton on
Nε2 of His23, together with the amide proton on Nε2 of
Trp202, can form the anchor for a carbonyl as well as for a
carboxyl group of the C-terminal P1′ substrate residue
(Figures 6 and 7). This confirms the proposal based on a
homology model of cathepsin X [26]. In order to create an
open S2′ substrate-binding site, the His23 ring has to move
out of the place occupied in the crystal structure. Simple
rotation about the χ1 and χ2 angles of the histidine can bring
the imidazole ring into a position equivalent to that occu-
pied by His110 in cathepsin B, where the two 
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Figure 5
The structure of cathepsin B (thin lines) in
complex with the CA030 inhibitor (thick lines)
superimposed on the structure of cathepsin X
(medium lines). The His23 ring that can be
rotated to the cathepsin-B-like position is
shown in bold dashed lines.
Figure 6
Carboxy-peptidase activity of cathepsin X.
(a) The surface of the active-site cleft region
of cathepsin X is colored according to
electrostatic potential, whereas the surface of
the catalytic Cys31 residue is shown in
yellow. The modeled substrate AFFW is
shown in ball-and-stick representation. Atoms
are represented as small spheres, color-
coded as in Figure 3. This figure was
prepared with WebLab ViewerLite (Molecular
Simulations Incorporated, San Diego, CA).
(b) Schematic representation of the substrate
binding. The substrate (thick line) has been
modeled into the active-site cleft of cathepsin
X (thin lines). Hydrogen bonds and disulfide
bridges are shown as dashed lines. 
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histidines His110 and His111 [33,37] bind the carboxyl
group of a substrate (Figure 5). Cathepsin X has no equiva-
lent residue to His111 of cathepsin B and therefore inter-
acts with only one carboxyl group oxygen atom of a
substrate. This explains why cathepsin X does not differen-
tiate between the substrates with blocked and free C-termi-
nal carboxylic group (I.K. et al., unpublished observations).
The flip-flop of the His23 sidechain between the confor-
mation observed in the crystal structure and the cathepsin
B-like conformation is most probably a substrate-induced
mechanism. The carboxy-dipeptidase activity appears to
be defined by the affinity of cathepsin X for the residue
binding into the S1 binding site. Arginine is preferred over
phenylalanine to such an extent that, instead of accepting
an arginine residue in the S2 binding site, the enzyme
modifies the binding pattern by shifting the arginine into
the P1 position (I.K. et al., unpublished observations).
Thereby two binding sites on the prime site are made
available and carboxy-dipeptidase activity is exhibited.
From our modeling study it is not evident whether a bound
P1 residue sidechain results in a shift of the Tyr27 ring,
which then assists in displacement of the His23 sidechain.
This is an issue that requires  further investigation.
Binding of protein inhibitors
In contrast to the initial report [26], cathepsin X can be
inhibited with various cystatin-type protease inhibitors
such as cystatin C and stefin A with Ki values in the
nanomolar range (I.K. et al., unpublished observations),
similar to those obtained for the inhibition of cathepsin B
[30]. A modeling study based on the papain–stefin B
complex [38] has shown that the sidechains of His23 and
Tyr27 clash with residues Val55 and Ala56 in the QVVAG
region (data not shown). A similar situation occurs in
cathepsin B, in which a cystatin-type inhibitor competes
with occluding loop residues for binding into the active-
site cleft [39,40]. The obvious solution appears to be that
the sidechains of His23 and Tyr27 are displaced when a
complex with a cystatin inhibitor is formed. Our modeling
study suggests that the ring of His23 flips away into its
cathepsin B-like position and the ring of Tyr27 rotates
into the S1 substrate-binding site.
Specific inhibitor design
The primary goal of the design of specific inhibitors of
lysosomal cysteine proteases is to establish the biological
role of a particular enzyme. Cross reactivity is likely to
lead to wrong conclusions. The relatively wide tissue dis-
tribution and abundance of cathepsin X [23,24] are similar
to those of cathepsin B. Because CA074 has been shown
to interact similarly with cathepsins X and B, it is evident
that physiological studies based on the use of this inhibitor
have to be repeated in order to clarify whether cathepsin B
or cathepsin X, or perhaps both enzymes, are implicated.
The structure of cathepsin X in a putative complex with
CA030, which was generated by superposition of the
structure of cathepsin B complexed with CA030 [37] on
the structure of cathepsin X, provides the first hints for
the design of inhibitors able to differentiate between the
two enzymes (Figure 5). CA030 is a very close analog of
CA074 (Figure 4): the inhibitors do not differ in the parts
that interact with the primed binding sites of the
enzymes. The only difference is in the nonprimed side,
where an ester-tail instead of an amide-tail points towards
the S2 binding site. In order to convert CA074 into a
selective inhibitor of cathepsin X, the following modifica-
tions appear evident. Firstly, a compound with a single
amino acid residue instead of two could be attached to an
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Figure 7
Carboxy-dipeptidase activity of cathepsin X.
His23 in the cathepsin X active site has been
rotated to the cathepsin-B-like position.
(a) The same color coding as in Figure 6 is
used. The model of substrate AFRFW is
shown in ball-and-stick representation.
(b) Schematic representation of the substrate
binding. The substrate (thick line) has been
modeled into the active-site cleft of cathepsin
X (thin lines). Hydrogen bonds and disulfide
bridges are shown as dashed lines.
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epoxysuccinyl reactive group and bind to His23 of cathep-
sin X and thus be too short to reach the His110 and
His111 residues on the surface of cathepsin B. Secondly, a
bulkier residue than isoleucine of CA074 could fill the S1′
site of cathepsin X and simultaneously not be able to bind
the smaller S1′ site of cathepsin B. Thirdly, the carboxyl
group of CA074 could be modified to interfere with the
binding to cathepsin B residue His111 and binding to
cathepsin X would remain unaffected.
The reverse case, the design of an inhibitor that will
inhibit only cathepsin B and not cathepsin X (and others)
seems a more difficult problem. One solution might be to
enlarge the cathepsin B inhibitor by expanding the inter-
action region to the nonprimed binding sites. It is known
that the specificity of papain-like cysteine proteases is par-
ticularly encoded in the S2 and S1′ substrate binding sites
[31,32]. A large number of small organic compounds react
chemically with the reactive site sulfhydryl of a cysteine
protease [31]. Most of these inhibitors interact only with
one half of the active-site cleft on the ‘nonprimed’ side. A
selective inhibitor of cathepsin B should probably span
the active site from the S2 to the S2′ binding site, as has
already been suggested [37]. Such a setup has been shown
to be quite successful in the cases of lysosomal cysteine
endopeptidases, cathepsins L, S and K [41,42], whereas
the potent double-headed inhibitors of cathepsin B might
now require additional improvements [43,44]. The selec-
tive cathepsin B inhibitor should, therefore, exploit the
‘primed’ substrate binding sites S1′ and S2′ as well as
reach into the S2 binding pocket, in which it should opti-
mally utilize the fit against the cathepsin B residues Pro76
and Glu245 and at the same time repel the equivalent
cathepsin X residues Asp76 and His234.
Biological implications
Lysosomal cysteine proteases are involved in a number
of physiological and pathological events. Although
similar in sequence and fold, they exhibit diversity in
localization, substrate and inhibitor specificity and sta-
bility. With the discovery of new members of the group,
the perception that the role of lysosomal cysteine pro-
teases is limited to the nonselective degradation of pro-
teins in lysosomes is changing. There is a growing body
of evidence that they work in concert. For example, they
appear to be involved in the strictly regulated matura-
tion of major histocompatibility complex (MHC) class II
molecules and antigen presentation [2].
It is not surprising that the discovery of each new
enzyme might require reconsideration of current knowl-
edge. In the case of cathepsin X it is evident that new
inhibitors should be developed in order to re-evaluate
the role(s) of cathepsin B. The crystal structure of
cathepsin X presented here reveals the differences and
similarities between the structures of the active sites of
the two enzymes. The structure of cathepsin X with a
rotated His23 ring, superimposed on the structure of the
complex of CA030 with cathepsin B and models of sub-
strates AFFW and AFRFW, explains the dual capabil-
ity of cathepsin X to exhibit carboxy-monopeptidase and
carboxy-dipeptidase activities and thus provide the basis
for design of selective inhibitors of cathepsin B.
Although cathepsin X was unknown until recently, it
has already been involved in an industrial application
[25,27]. It is held responsible for the cleavage of β-
amyloid peptide, which can, when secreted from the cells
and accumulated in amyloid plaques, result in
Alzheimer’s disease. Inhibition of its activity was pro-
posed to slow-down the progress of the disease and, if
diagnosed in time, even prevent its manifestation. It
should be noted that this role of cathepsin X is based on
an inhibition study and might thus require additional
clarification.
Materials and methods
Crystallization and data collection
Cathepsin X was isolated from human liver (I.K. et al., unpublished
observations). The purified cathepsin X was concentrated to a concen-
tration of 8.8 mg/ml in a spin concentrator (Centricon; Amicon). Crys-
tals were grown using the sitting-drop vapor diffusion method. The
reservoir contained 1 ml 14.4% PEG 4000, 7.2% 2-propanol and
0.072 M Na-HEPES adjusted to pH 8.0. The drop was composed of
2.2 µl reservoir solution and 2.8 µl protein (8.8 mg/ml) in 20 mM Na-
acetate and 1 mM EDTA pH 5.1.
Diffraction data were collected from a single crystal using Cu Kα radia-
tion from a Rigaku Ru200 rotating-anode X-ray generator and recorded
on a 345 mm MAR Research image-plate detector. Although crystals
diffracted to a higher resolution at synchrotron, we did not use synchro-
tron data sets because of increased mosaicity of the frozen crystals.
Auto indexing and scaling was done using the programs MOSFLM and
SCALA [45,46]. The crystal diffracted to 2.67 Å resolution and
belonged to the orthorhombic space group C2221 with cell dimen-
sions a = 62.3 Å, b = 92.5 Å, c = 209.9 Å. The asymmetric unit con-
tained two molecules. 
Structure determination and refinement
The structure of cathepsin X was solved using the molecular replace-
ment method implemented in EPMR program [47]. The crystal struc-
ture of actinidin [48] was used as the search model. Two solutions with
a correlation factor of 0.311 and an R value of 0.54 were found using
data in the 15–4 Å resolution range.
In the subsequent structure determination, the program MAIN [49] was
used for density modifications, model building and refinement. The first
electron-density map was calculated with two actinidin molecules [48].
The noninterpreted regions of the electron density were masked with
atoms, superimposed and averaged. Density of the solvent region was
flipped with the factor 0.3. After completing the model using data to
3.0 Å resolution, the resolution of the data was gradually expanded to
the final range (10.0–2.67 Å) in subsequent cycles that involved model
rebuilding, positional and B-value refinement, density averaging and
solvent generation. Standard parameters for protein [50] were used for
geometry regularization. Averaged kicked omit-maps were used
throughout the structure determination process to reveal ambiguous
parts of the structure. The averaged kicked omit-maps were calculated
by adding eight difference omit-maps, each resulting from a corre-
sponding set of randomly displaced atoms, up to 0.8 Å along each
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coordinate. After the crystallographic R value dropped below 0.25 at
2.7 Å resolution, the temperature-factor refinement was applied. Water
molecules were generated using an automatic procedure in MAIN and
then corrected manually.
The final refinement included all reflections (cutoff 1σ) in the resolution
range 10–2.67 Å, with the crystallographic R value being 0.183. The
geometry of the final model was inspected with MAIN and
PROCHECK [51]. All residues lie in the allowed regions of the
Ramachandran plot, 0.825 of residues in most favored regions and
0.175 in additional allowed regions. Other structural parameters for the
structure refined at this resolution show no significant deviations from
the expected values (overall G factor is 0.2, which is better than
expected for 2.67 Å resolution). The crystallographic data and refine-
ment statistics are summarized in (Table 1).
Accession numbers
The coordinates have been deposited in the Protein Data Bank with
accession code 1EF7 and will be on hold for one year.
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